Nipro develops MSC for treatment of spinal cord injury

According to Nipro’s president Yoshihiko Sano during a financial results briefing, Nipro has entered into a license agreement with Sapporo Medical University and develops autologous bone marrow-derived mesenchymal stem cells (MSC) for the treatment of cerebral infarction and spinal cord injury. The company will apply for approval in 2017 including manufacturing capacities.

Nikkei Biotech news release, May 19, 2017

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny